Browsing by Subject "Tumor marker"
Now showing items 1-20 of 20
-
Article
Angiogenesis in cancer of unknown primary: Clinicopathological study of CD34, VEGF and TSP-1
(2005)Background: Cancer of unknown primary remains a mallignancy of elusive biology and grim prognosis that lacks effective therapeutic options. We investigated angiogenesis in cancer of unknown primary to expand our knowledge ...
-
Article
Cancer of unknown primary origin
(1997)About 3 % of all cancer patients suffer from cancer of unknown primary origin. These patients present with metastatic disease for which a primary site cannot be detected at the time of diagnosis. Sophisticated diagnostic ...
-
Article
Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer
(2015)Cancer of Unknown Primary (CUP) comprises a heterogeneous disease group with diagnosis of metastatic malignancy in the absence of an identifiable primary site after diagnostic work up. CUP may either resemble a specific ...
-
Article
Cancer of unknown primary patients with midline nodal distribution: Midway between poor and favourable prognosis?
(2011)Background: Midline nodal cancer of unknown primary (CUP) has varying definitions and an unclear natural history compared to that of extragonadal germ cell cancer (EGCC) and neuroendocrine tumors. Methods: We systematically ...
-
Article
Cancer of unknown primary site: 20 questions to be answered
(2010)Cancer of unknown primary (CUP) is a common, well-recognized and heterogeneous clinical syndrome. Patients with CUP present with metastatic disease in the absence of an identifiable primary tumour despite a diagnostic ...
-
Article
Carcinoma of unknown primary (CUP)
(2009)Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests ...
-
Article
CENP-B specific anti-centromere autoantibodies heralding small-cell lung cancer. A case study and review of the literature
(2008)We report on a small-cell lung cancer case that was heralded by the presence of CENP-B specific anti-centromere autoantibodies (ACA) detected well before the diagnosis of cancer. The patient received chemotherapy plus ...
-
Article
Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients
(1996)A total of 209 postsurgical breast cancer patients were prospectively monitored with simultaneous serum level estimations of CA 15-3, mucin-like carcinoma-associated antigen (MCA), tumor polypeptide antigen (TPA), and ...
-
Article
Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma
(2006)The aim of the study was to investigate angiogenesis in patients with advanced-stage ovarian carcinoma. We used paraffin-embedded tumor tissues from 33 patients diagnosed with FIGO III ovarian cancer who had optimal surgery ...
-
Article
Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors
(2006)Metallothioneins (MTs) are a family of cystein-rich metal-binding proteins, which are expressed in normal cells during fetal and postnatal life but also in a variety of human neoplasms. MT expression in human tumors has ...
-
Article
Five tumor markers in lung cancer: Significance of total and>-Bound sialic acid
(1991)Total sialic acid (TSA) and > sialic acid (LSA) were evaluated in comparison to carcinoembryonic antigen (CEA) and ferritin and neuron specific enolase (NSE) in 152 untreated patients with primary lung cancer, 107 benign ...
-
Article
Matrix metalloproteinases in carcinoma of unknown primary
(2005)BACKGROUND. The purpose was to study proteolysis-related molecules, matrix metalloproteinase-2 (MMP-2) and MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1), in carcinoma of unknown primary (CUP). METHODS. ...
-
Article
Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx
(2012)Angiogenesis is active in localised laryngeal squamous cell carcinoma. We assessed relative messenger RNA (mRNA) and immunohistochemical (IHC) expression of Vascular Endothelial Growth Factors (VEGF) A, B, C, their receptors ...
-
Article
Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper
(2015)While they account for one-fifth of new cancer cases, rare cancers are difficult to study. A higher than average degree of uncertainty should be accommodated for clinical as well as for population-based decision making. ...
-
Article
-
Article
Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients
(1995)The levels of soluble interleulkin-2 receptors (sIL-R2) were measured in the serum of 52 patients with epithelial ovarian carcinoma as well as in 25 age and sex-matched normal controls. The mean serum level of sIL-2R was ...
-
Article
Serum‐soluble interleukin‐2 receptors in B‐cell lymphoproliferative malignancies
(1992)The levels of soluble interleukin‐2 receptors (sIL‐2R) were determined in the serum of 53 patients with B‐cell lymphoproliferative malignancies, including 31 patients with non‐Hodgkin lymphomas (NHL), 16 with chronic ...
-
Article
Soluble interleukin-2 receptors in patients with advanced colorectal carcinoma
(1996)The levels of soluble interleukin-2 receptors (sIL-2R) were measured in the serum of 52 patients with advanced colorectal carcinoma and compared to CEA and CA 19-9 levels. Twenty-five normal, age and sex-matched individuals ...
-
Article
The value of CA-125 determination in the serum of patients with non-Hodgkin's lymphomas. A preliminary report
(1994)The levels of CA 19-9, CA 15-3 and CA 125 in the serum of 50 patients with non-Hodgkin's lymphomas (NHL) were investigated. Mean values of these serum tumor markers were compared to stage, presence or absence of B-symptoms, ...
-
Article
The value of neuroendocrine markers in non-small cell lung cancer: a comparative immunohistopathologic study
(1994)In order to estimate the value of immunohistochemical identification of neuroendocrine (NE) differentiation markers in non-small cell lung carcinomas (NSCLCs), we investigated the expression of five neuroendocrine and ...